# CAPR catalysts: CAPRICOR THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/capr/catalysts

> CAPRICOR THERAPEUTICS, INC. (CAPR) has 2 upcoming catalysts. The next is the deramiocel PDUFA date, November 22, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CAPR?

CAPRICOR THERAPEUTICS, INC. (CAPR) has 2 upcoming catalysts. The next is the deramiocel PDUFA date, November 22, 2026. Press release filed with the SEC (EX-99): "Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026" [Calendar and source filings](https://sec-api.dev/companies/capr/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-125150, https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/capr/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | CAPRICOR THERAPEUTICS, INC. |
| Ticker | CAPR (Nasdaq) |
| SEC CIK | 1133869 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/capr |

## Cash runway

Cash $197.6M as of 2026-09-30; quarterly burn $35.7M; about 16.6 months of runway at that rate (XBRL company facts, accession 0001104659-26-125355).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| late 2024 | [Deramiocel NDA/BLA submission](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | scheduled | "Rolling BLA submission initiated in October 2024 with full submission expected by year-end 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/capr-20241113xex99d1.htm)) |
| November 13, 2024 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/capr-20241113xex99d1.htm)) |
| Dec 2024 | [Deramiocel NDA/BLA acceptance](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | completed | "We completed the full submission of the BLA in December 2024 and in the first quarter of 2025, we were informed by the FDA, they have accepted for review our BLA seeking full approval for deramiocel as a treatment for patients diagnosed with DMD cardiomyopathy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007770/capr-20250331x10q.htm)) |
| January 2, 2025 | [Deramiocel NDA/BLA submission](https://sec-api.dev/pdufa/deramiocel) | CAPR | diagnosed with Duchenne muscular dystrophy | completed | "On January 2, 2025, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that it has completed the submission of its Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000155837025000010/capr-20250102x8k.htm)) |
| March 4, 2025 | [Deramiocel NDA/BLA acceptance](https://sec-api.dev/pdufa/deramiocel) | CAPR | rare diseases, today | completed | "On March 4, 2025, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing announced that the U.S. Food and Drug Administration ("FDA") has accepted for review its Biologics License Application ("BLA") seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/capr-20250304x8k.htm)) |
| March 19, 2025 | [Deramiocel NDA/BLA acceptance](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed | "Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm)) |
| March 19, 2025 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm)) |
| May 13, 2025 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm)) |
| June 18, 2025 | [Deramiocel primary completion](https://sec-api.dev/pdufa/deramiocel) | CAPR | Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic | completed | "NCT05126758 (A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-18 (ACTUAL); Lead Sponsor Capricor Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05126758)) |
| Q3 2025 | [StealthX (stealthx) trial start](https://sec-api.dev/pdufa/stealthx) | CAPR |  | scheduled | "The National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the third quarter of 2025, subject to NIAID's regulatory approval" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm)) |
| Q3 2025 | [Deramiocel topline data readout](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | scheduled | "The HOPE-3 trial is a randomized, double-blind, placebo-controlled clinical trial of 104 patients, with topline results expected in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/capr-20250711xex99d1.htm)) |
| Jul 2025 | [CAPRICOR THERAPEUTICS, INC. complete response letter (CRL)](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed, complete response letter | "In July 2025, the Company received a Complete Response Letter ("CRL") from the FDA stating that the current BLA did not meet the statutory requirement for substantial evidence of effectiveness and that additional clinical data would be required." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109298/capr-20250930x10q.htm)) |
| July 9, 2025 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR | cardiomyopathy associated with Duchenne muscular dystrophy | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/09/2025 for BL 125842 to Capricor, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125842_20250709.pdf%22)) |
| Aug 2025 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | completed, complete response letter | "Recent Type A meeting with FDA: In August 2025, Capricor held a Type A meeting with FDA following receipt of a Complete Response Letter (CRL) for its Biologics License Application (BLA) for Deramiocel." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm)) |
| Aug 2025 | [Deramiocel trial start](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | scheduled | "The Phase 1 clinical trial, conducted and funded by NIAID, was initiated in August 2025, with dosing of the first subject expected imminently." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm)) |
| August 11, 2025 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm)) |
| August 31, 2025 | [CAPRICOR THERAPEUTICS, INC. PDUFA date](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | scheduled | "In early 2025, the FDA accepted the application for review, granted Priority Review status, and assigned a Prescription Drug User Fee Act ("PDUFA") target action date of August 31, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109298/capr-20250930x10q.htm)) |
| August 31, 2025 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm)) |
| Q4 2025 | [Deramiocel topline data readout](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | scheduled | "Topline results are expected in the coming weeks (Q4 2025)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm)) |
| Q4 2025 | [Deramiocel NDA/BLA submission](https://sec-api.dev/pdufa/deramiocel) | CAPR | cardiomyopathy associated with Duchenne muscular dystrophy | scheduled | "Capricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm)) |
| November 10, 2025 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm)) |
| December 3, 2025 | [Deramiocel topline data readout](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, positive | "SAN DIEGO, Dec. 3, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925117947/capr-20251203xex99d1.htm)) |
| Q1 2026 | [StealthX (stealthx) interim data readout](https://sec-api.dev/pdufa/stealthx) | CAPR |  | scheduled | "NIAID-sponsored Phase 1 clinical trial underway with StealthX™ exosome-based vaccine; initial topline data currently expected in the first quarter of 2026, subject to completion by NIAID" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm)) |
| March 10, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | completed, complete response letter | "Press Release, titled "Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA", dated March 10, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm)) |
| March 10, 2026 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "On March 10, 2026, Capricor Therapeutics, Inc. (the "Company" or "Caprcior") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has lifted the previously issued Complete Response Letter ("CRL") and resumed review of its Biologics License Application ("BLA") seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy ("DMD") cardiomyopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm)) |
| March 12, 2026 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/capr-20260312xex99d1.htm)) |
| May 12, 2026 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm)) |
| June 26, 2026 | [Deramiocel FDA advisory committee meeting](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | scheduled | "On June 26, 2026, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration ("FDA") is planning to convene an Advisory Committee meeting to discuss the Company's Biologics License Application ("BLA") seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy ("DMD")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm)) |
| Jul 2026 | [Deramiocel NDA/BLA submission](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | completed | "As part of its ongoing discussions with the FDA following the July 2026 Advisory Committee meeting, Capricor submitted an amendment to the BLA that includes 24-month open-label extension data from its pivotal Phase 3 HOPE-3 study and additional robustness analyses, with a request that the FDA review the existing and new data in support of a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm)) |
| July 29, 2026 | [Deramiocel FDA advisory committee meeting](https://sec-api.dev/pdufa/deramiocel) | CAPR | treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD) | completed, mixed | "On July 29, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125842 from Capricor, Inc. for deramiocel (human allogeneic cardiosphere-derived cells) the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated)) |
| August 10, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | delayed | "NS Pharma Dispute: The state court was scheduled to hear Capricor's motion for preliminary injunction on August 10, 2026, ahead of the PDUFA action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm)) |
| August 13, 2026 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm)) |
| August 22, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | scheduled | "--Deramiocel BLA Remains Under Active FDA Review, with PDUFA Target Action Date of August 22, 2026--" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729xex99d1.htm)) |
| August 24, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | delayed | "Press Release, titled "Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA", dated August 24, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824x8k.htm)) |
| November 10, 2026 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm)) |
| November 22, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | rare diseases, today | scheduled | "Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm)) |
| November 22, 2027 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | scheduled | "Following the FDA's extension of the PDUFA target action date to November 22, 2026, the Company updated its estimated contractual and rent commencement dates to November 22, 2026 and November 22, 2027, respectively, and remeasured the lease, resulting in an increase to the lease liability and the ROU asset of approximately $73,000." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm)) |

## Drugs

- [Deramiocel](https://sec-api.dev/pdufa/deramiocel): duchenne muscular dystrophy, rare diseases, today, cardiomyopathy associated with duchenne muscular dystrophy, cardiomyopathy in patients with dmd, cardiomyopathy in patients with duchenne muscular dystrophy, duchenne muscular dystrophy", dated june 26, 2026, treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD), Muscular Dystrophies
- [StealthX (stealthx)](https://sec-api.dev/pdufa/stealthx): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/capr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CAPR catalysts: CAPRICOR THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/capr/catalysts

```bibtex
@misc{secapidev_companies_capr_catalysts_20261116,
  title        = {CAPR catalysts: CAPRICOR THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/capr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_capr_catalysts_20261116","title":"CAPR catalysts: CAPRICOR THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/capr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
